SCHEMBL7828891

SCHEMBL7828891

O=[N+]([O-])c1ccc(-n2nccn2)c(F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
KMT2A Q03164 3/20 0.57
LMNA P02545 3/20 0.49
HIF1A Q16665 1/20 0.47
MAPT P10636 3/20 0.44
THRB P10828 1/20 0.44
CASP1 P29466 1/20 0.43
CASP3 P42574 1/20 0.43
CASP4 P49662 1/20 0.43
CASP7 P55210 1/20 0.43
CASP9 P55211 1/20 0.43
CASP6 P55212 1/20 0.43
POLB P06746 1/20 0.41
MEN1 O00255 2/20 0.41
DPP4 P27487 1/20 0.40
SLC22A12 Q96S37 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17292927 0.80 HSD17B10 (0.55) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL2627310 0.80 ALDH1A1 (0.55) ALDH1A1KMT2ALMNAMAPTCASP1
SCHEMBL19817232 0.80 ALDH1A1 (0.40) ALDH1A1KMT2ALMNAHIF1AMAPT
SCHEMBL25259776 0.80 PDE7A (0.44) ALDH1A1KMT2ACASP1CASP3CASP4
SCHEMBL1353531 0.78 ALDH1A1 (0.57) ALDH1A1KMT2ALMNAHIF1AMAPT
SCHEMBL31463575 0.77 ALDH1A1 (0.54) ALDH1A1KMT2ALMNAHIF1AMAPT
SCHEMBL31284553 0.77 ALDH1A1 (0.55) ALDH1A1KMT2AMAPTCASP1CASP3
SCHEMBL31284605 0.76 ABCC8 (0.41) ALDH1A1KMT2ACASP1CASP3CASP4
SCHEMBL19814271 0.76 ALDH1A1 (0.62) ALDH1A1KMT2ALMNAMAPTCASP1
SCHEMBL14464189 0.76 ALDH1A1 (0.79) ALDH1A1KMT2ALMNAMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834449-B2 TYK2 inhibitors and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-12-05 US disclosed
CN-1075073-C Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials UPJOHN CO (US) 2001-11-21 CN disclosed
EP-0807112-B1 HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS UPJOHN CO (US) 2001-09-05 EP disclosed
US-6124334-A A BACTERICIDE TREATING INFECTIONS CAUSED BY GRAM-POSITIVE AEROBIC BACTERIA SUCH AS STAPHYLOCOCCUS, STREPTOCOCCUS AND ENTEROCOCCUS AS WELL AS ANAEROBIC ORGANISMS SUCH AS BACTEROIDES AND CLOSTRIDIUM AND MYCOBACTERIDIUM PHARMACIA & UPJOHN COMPANY (US) 2000-09-26 US disclosed
US-5910504-A BACTERICIDES TREATING INFECTIONS PHARMACIA & UPJOHN (US) 1999-06-08 US disclosed
CN-1172484-A Phenyl oxazolidinone antibacterial agents substituted with heteroaromatic rings UPJOHN CO (US) 1998-02-04 CN disclosed
EP-0807112-A1 HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS PHARMACIA & UPJOHN COMPANY (US) 1997-11-19 EP disclosed
WO-1996023788-A1 HETERO-AROMATIC RING SUBSTITUTED PHENYLOXAZOLIDINONE ANTIMICROBIALS PHARMACIA + UPJOHN COMPANY (US) 1996-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11834449-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 ALDH1A1 4827/4885KMT2A 206/4885LMNA 2078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.